Acadia Pharmaceuticals
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase IV development as a treatment for Parkinson's disease psychosis. It is also developing AGN XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. The product candidates in the company's pipeline emanate from discoveries made using its proprietary drug discovery platform.
Wikipage disambiguates
Wikipage redirect
primaryTopic
Acadia Pharmaceuticals
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase IV development as a treatment for Parkinson's disease psychosis. It is also developing AGN XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. The product candidates in the company's pipeline emanate from discoveries made using its proprietary drug discovery platform.
has abstract
ACADIA Pharmaceuticals, Inc. i ...... etary drug discovery platform.
@en
founding year
industry
key person
net income ($)
number of employees
operating income ($)
product
revenue ($)
thumbnail
type
Wikipage page ID
31,349,406
Wikipage revision ID
742,350,222
assets
subject
comment
ACADIA Pharmaceuticals, Inc. i ...... etary drug discovery platform.
@en
label
Acadia Pharmaceuticals
@en
wasDerivedFrom
depiction
isPrimaryTopicOf
name
Acadia Pharmaceuticals
@en